tbuckley/cabot-search huggingface dataset:
Differential effects of dietary supplements on metabolomic profile of smokers versus non-smokers
Authors: Robert C Spitale, Michelle Y Cheng, Kimberley A Chun, Emily S Gorell, Claudia A Munoz, Dale G Kern, Steve M Wood, Helen E Knaggs, Jacob Wulff, Kirk D Beebe, Anne L S Chang
Journal: Genome Medicine (2012)

Cigarette smoking is well-known to associate with accelerated skin aging as well as cardiovascular disease and lung cancer, in large part due to oxidative stress. Because metabolites are downstream of genetic variation, as well as transcriptional changes and post-translational modifications of proteins, they are the most proximal reporters of disease states or reversal of disease states. In this study, we explore the potential effects of commonly available oral supplements (containing antioxidants, vitamins and omega-3 fatty acids) on the metabolomes of smokers (n = 11) compared to non-smokers (n = 17). At baseline and after 12 weeks of supplementation, metabolomic analysis was performed on serum by liquid and gas chromatography with mass spectroscopy (LC-MS and GC-MS). Furthermore, clinical parameters of skin aging, including cutometry as assessed by three dermatologist raters blinded to subjects' age and smoking status, were measured. Long-chain fatty acids, including palmitate and oleate, decreased in smokers by 0.76-fold (P = 0.0045) and 0.72-fold (P = 0.0112), respectively. These changes were not observed in non-smokers. Furthermore, age and smoking status showed increased glow (P = 0.004) and a decrease in fine wrinkling (P = 0.038). Cutometry showed an increase in skin elasticity in smokers (P = 0.049) but not in non-smokers. Complexion analysis software (VISIA) revealed decreases in the number of ultraviolet spots (P = 0.031), and cutometry showed increased elasticity (P = 0.05) in smokers but not non-smokers. Additional future work may shed light on the specific mechanisms by which long-chain fatty acids can lead to increased glow, improved elasticity measures and decreased fine wrinkling in smokers' skin. Our study provides a novel, medicine-focused application of available metabolomic technology to identify changes in sera of human subjects with oxidative stress, and suggests that oral supplementation (in particular, commonly available antioxidants, vitamins and omega-3 fatty acids) affects these individuals in a way that is unique (compared to non-smokers) on a broad level.
HCV: Diagnosis and natural history
Authors: Yuehua Huang, Lin Gu, Xiaohui Huang, Laura Belloni, Lichun Li, Gianna Palumbo, Srinivas Reddy Chirapu, Ludovica Calvo, Mg Finn, Uri Lopatin, Adam Zlotnick, Massimo Levrero, Arevik Mosoian, Yedidya Hong, Adeeb Saiman, Sasan Rahman, Sander Roayaie, Francesc Florman, Mario Cunyat, Meena Stevenson
Journal: Hepatology (2013)

antibody.Expressions of cell cycle regulators (p21, p27, and p57) and AKT1 as well as its downstream gene S phase kinase associated protein 2 (SKP2) were examined in both human HCC tissues and HBV expressing Huh7 cells.Effects of coactivation of AKT1 and HBV mutations on cell cycle progression and celluar growth were also analysed.Results: When compared to patients with HCCB, KI67-positive cells and MVD were significantly higher, while apoptotic index was significantly lower in HCCP.Decreased levels of cell cycle regulators, and increased levels of AKT1 and SKP2 were more profound in HCCP than that in HCCB.Higher incidence of HBV CP mutations was significantly associated with HCCP when compared to HCCB (77.5% for HCCP and 27% for HCCB, respectively, p<0.05).The level of AKT1 expression correlated with enhanced proliferation and MVD, as well as the prevalence of CP mutations, and was inversely correlated with apoptosis and survival in HCC patients.HBV with CP mutations accelerated cell cycle regulators protein degradation while wild type HBV had no effect in Huh7 cells.These effects were accompanied by a profound increase in AKT1.Coexpression of AKT1 and HBV CP mutations resulted in a dramatic increase of SKP2 expression, which in turn accelerated cellular growth and cell cycle progression in hepatoma cells when compared with cells overexpresssing AKT1 or HBV CP mutant alone.Small interfering RNA knockdown of SKP2 abrogated the effect of CP mutations on levels of cell cycle regulators, decreased cell proliferation, and restored cell cycle arrest.Conclusion: Our data demonstrate the crosstalk between HBV CP mutations and AKT1 in promoting liver tumor progression, and suggest that AKT1/SKP2 signals may serve as a potential target for treamtment of HBV associated HCC.
Hip fractures and fluoridation in Utah's elderly population
Authors: C. Danielson
Journal: JAMA (1992)

<h3>Objective.</h3> —To test the effect of water fluoridated to 1 ppm on the incidence of hip fractures in the elderly. <h3>Design.</h3> —Ecological cohort. <h3>Setting.</h3> —The incidence of femoral neck fractures in patients 65 years of age or older was compared in three communities in Utah, one with and two without water fluoridated to 1 ppm. <h3>Patients.</h3> —All patients with hip fractures who were 65 years of age and older over a 7-year period in the three communities, excluding (1) those with revisions of hip fractures, (2) those in whom the hip fracture was anything but a first diagnosis, (3) those in whom metastatic disease was present, or (4) those in whom the fracture was a second fracture (n=246). <h3>Outcome Measure.</h3> —Rate of hospital discharge for hip fracture. <h3>Results.</h3> —The relative risk for hip fracture for women in the fluoridated area was 1.27 (95% confidence interval [CI]=1.08 to 1.46) and for men was 1.41 (95% CI=1.00 to 1.81) relative to the nonfluoridated areas. <h3>Conclusions.</h3> —We found a small but significant increase in the risk of hip fracture in both men and women exposed to artificial fluoridation at 1 ppm, suggesting that low levels of fluoride may increase the risk of hip fracture in the elderly. (<i>JAMA</i>. 1992;268:746-748)
Ischemia-reperfusion of rat myocardium activates NF-kB and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine Bysani Chandrasekar, Jeffrey B. Smith, Gregory L. Freeman. The University of Texas Health Science Center, San Antonio, TX, UCLA School of Medicine, Los Angeles, CA
Journal: Journal of the American College of Cardiology (2001)
Defining the elements of early palliative care (PC) that are associated with patient-reported outcomes (PROs) and the delivery of end-of-life (EOL) care.
Authors: Michael Hoerger, Jennifer S. Temel, Vicki Jackson, Elyse Park, William F. Pirl, Areej El-Jawahri, Emily R. Gallagher, Teresa Hagan, Juliet Jacobsen, Laura Perry, Joseph Greer
Journal: Journal of Clinical Oncology (2017)

154 Background: Early PC integrated with oncology care improves quality of life, mood and the delivery of EOL care among patients with advanced cancer, but little is known about which elements of PC practice are associated with such outcomes. The goals of this study were to describe the key elements of early PC across the illness trajectory and examine whether variation in visit content was associated with changes in PROs and the delivery of EOL care. Methods: The study cohort included patients with incurable lung or non-colorectal gastrointestinal cancer who were randomized to early PC integrated with oncology care (n = 171). Patients completed measures of quality of life (Functional Assessment of Cancer Therapy-General, FACT-G) and mood (Hospital Anxiety and Depression Scale, HADS; Patient Health Questionnaire–9, PHQ-9) at baseline and 24 weeks. PC clinicians completed electronic post-visit surveys documenting PC visit content. Data on EOL care were abstracted from electronic health records. We examined variation in visit content over time and used linear and logistic regression to identify whether the percentage of visits emphasizing a given content area was associated with PROs and EOL care. Results: We analyzed 2,921 PC visits, most of which focused on coping (64.2%) and symptom management (74.5%). By 24 weeks, patients who had a higher percentage of visits focused on coping experienced improved quality of life (p = .02) and depression (HADS: p = .002; PHQ-9: p = .005). Having a higher percentage of visits focused on treatment decisions was associated with a reduced odds of new chemotherapy (p = .02), hospitalization (p = .001), and ED admission (p = .04) in the 60 days prior to death. Focusing on advance care planning was associated with an increased odds of receiving hospice care (p = .01) and dying at home (p = .03). Conclusions: PC clinicians’ attention to coping is associated with improvements in PROs, and the focus on treatment decisions and advanced care planning is associated with higher quality EOL care. This study defines the key elements of early PC for patients with advanced cancer and furthers the development and dissemination of this integrated model of care. Clinical trial information: NCT01401907.
Council on drugs. List No. 83. New names
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Determination of Plasma Ammonia Nitrogen Concentration by Simple Ion Exchange Method
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
POSTGASTRECTOMY GASTRITIS
Authors: B J FICARRA
Journal: Annals of Internal Medicine (1944)

Article1 May 1944POSTGASTRECTOMY GASTRITISDONOVAN C. BROWNE, M.D., F.A.C.P., GORDON MCHARDY, M.D.DONOVAN C. BROWNE, M.D., F.A.C.P.Search for more papers by this author, GORDON MCHARDY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-20-5-789 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptNow that subtotal gastrectomy has survived two decades it is becoming obvious that the resultant alteration in contour and function of the stomach carries with it an appreciable morbidity. We are not debating the curative value of the procedure. Aside from the many mechanical complications about which much has been written critically and constructively by surgeons, there is a group of medical problems relegated to the internist for management which we have discussed in a recent publication1 and which we will merely list:1. Recurrent or anastomotic ulceration.2. Hemorrhage from ulceration or gastritis.3. Edematous stomal obstruction resulting from...Bibliography1. BROWNEMCHARDY DCG: The patient after gastric surgery, South. Med. Jr., 1943, xxxvi, 32-41. CrossrefGoogle Scholar2. SCHINDLER R: Gastroscopy, 1937, University of Chicago Press, Chicago, pp. 275-277. Google Scholar3. SCHINDLER R: Gastroscopic observations in resected stomachs, Am. Jr. Digest. Dis., 1940, vii, 505-512. CrossrefGoogle Scholar4. WANKE R: Quoted by Schindler.2 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New Orleans, Louisiana*Delivered before the Regional meeting, American College of Physicians, New Orleans, April 16, 1943.From the Department of Medicine, School of Medicine, Tulane University of Louisiana, and the Gastroenterology Clinic of Touro Infirmary, New Orleans, Louisiana. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDuodenogastric reflux after gastric operationsAlkaline reflux gastritis: A myth or a disease?Postoperative Reflux GastritisDie Krankheiten des MagensPostgastrectomy Gastritis 1 May 1944Volume 20, Issue 5Page: 789-792KeywordsGastrectomyGastritisHemorrhageMorbidityPostgastrectomyStomachSurgeonsUlcers ePublished: 1 December 2008 Issue Published: 1 May 1944 PDF downloadLoading ...
Abstract 2268: Agonistic T cell non depleting ICOS antibody strongly enhances anti-tumor activity with CTLA4 blocking monoclonal antibody without exacerbating colitis
Authors: Clélia Coutzac, Jean Jouniaux, Aurore Vozy, Marc Ballas, Sara Brett, Sapna Yadavilli, Eric Angevin, Axel Hoos, Nathalie Chaput
Journal: Cancer Research (2019)

Abstract Background: ICOS is a member of the CD28 superfamily mainly expressed on activated T cells. An up-regulation of ICOS+ T cells is observed in patients treated with ipilimumab. These findings prompt further studies examining the synergy between CTLA-4 blockade and ICOS stimulation in generating optimal anti-tumor T cell immunity. Methods: Peripheral blood mononuclear cells (PBMC) were collected from French patients with metastatic melanoma and treated with ipilimumab at baseline (V1) and after 1-2 ipilimumab infusion and restimulated in vitro with anti-CD3 plus anti-human non-depleting agonist ICOS IgG4 isotype antibodies. T cell proliferation and cytokine secretion was determined after 24 and 48h incubation. For in vivo experiments, C57Bl/6 and BALB/c mice were inoculated subcutaneously with MC38 and CT26 tumor cell lines respectively. Mice received intraperitoneal injections of anti-CTLA4 or its isotype control along with anti-mouse ICOS or corresponding isotype at D7, D10 and D13 with tumor growth assessments three times a week. Results: PBMC collected from patients that respond to anti-CTLA-4 mAb exhibited stronger activation of T cells at baseline compared to patients with poor benefit. Treatment with a non-depleting agonist ICOS IgG4 mAb was able to rescue T cell activation in PBMC from patients with poor benefit. Furthermore, ICOS IgG4 with concurrent TCR engagement favored IL-10 secretion in patients that do not develop colitis during ipilimumab treatment suggesting that these patients may be protected from colitis due to a stronger capacity to secrete IL-10 after ipilimumab blockade particularly when ICOS is stimulated. In both mouse tumor models, combination with agonist non-depleting ICOS mAb increased the anti-CTLA-4 tumor activity without any colitis development. Conclusion: This study provides evidence in mice and in humans that non-depleting agonistic ICOS mAb may increase anti-CTLA-4 tumor activity particularly in patients that do not benefit from anti-CTLA-4 alone without exacerbation of colitis. Citation Format: Clélia Coutzac, Jean Jouniaux, Aurore Vozy, Marc Ballas, Sara Brett, Sapna Yadavilli, Eric Angevin, Axel Hoos, Nathalie Chaput. Agonistic T cell non depleting ICOS antibody strongly enhances anti-tumor activity with CTLA4 blocking monoclonal antibody without exacerbating colitis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2268.
Author index
Authors: F Cosan, A Yazici, A Cefle, A Gul
Journal: Annals of the Rheumatic Diseases (2010)

Background Tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autosomal dominantly inherited rare autoinfl ammatory disease.It caused by mutations in exon 2-3 and 4-5 of the TNFRSF1A gene on chromosome 12p13.2.TNFRSF1A gene encodes the 55 kDa receptor for TNF.Attacks are associated with abdominal pain, myalgia, erythematous skin rash, conjunctivitis and periorbital oedema.More than 80 mutations have so far been identifi ed.The authors report three patients of Turkish origin with TRAPS.Patients and Methods The patients were followed in our outpatient clinic in Kocaeli University Division of Rheumatology.Because of their TRAPS-associated clinical features, the authors isolated genomic DNA from whole blood and sequenced the exon 2-3 and 4-5 third exon of TNFRSF1A gene after amplification with appropriate primers.Results One of the patients with TRAPS, a 47-year-old woman, described recurrent attacks of fever, urticarial rash, conjunctivitis, athralgia, myalgia, abdominal pain, thoracic pain, headache, fatigue and elevated acute phase response since her childhood.With sequencing of the TNFRSF1A gene, the authors identifi ed heterozygous C29R mutation which has not been reported before in any TRAPS patient.The other patients were her sons (aged 29 and 26 years) with similar fi ndings in whom the authors also found a heterozygous C29R mutation. ConclusionThe authors report a novel C29R mutation in three patients of Turkish origin with TRAPS in whom the main clinical features were recurrent fever attacks, erythematous skin rash, conjunctivitis, myalgia and arthralgia.Treatment with steroids completely resolved the symptoms and lesions.on August 20,
Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans
Authors: P. C. Rittershaus, T. B. Kechichian, J. C. Allegood, A. H. Merrill, M. Hennig, C. Luberto, M. Del Poeta
Journal: Journal of Clinical Investigation (2007)

During the preparation of the manuscript, an error was introduced into the series of oligonucleotide primer sequences on page 1455.The sequence for the Vβ18 primer was inadvertently given for the constant region of the TCR β-chain (Cβ) as well.The correct Cβ sequence is 5'-GGCTCAAACAAGGAGACCTTGGGTGG-3'.
Laparoscopy, videosession
Authors: G Varga, H Wong, J Walsh, D Campbell, T Solomon, A Antal, P Ezer, P Schmidt, F Korompai
Journal: Gut (1994)

Laparoscopic cholecystectomy is a minimally invasive procedure whereby the gallbladder and gallstones are removed using laparoscopic techniques.We performed 1500 laparoscopic cholecystectomies using mechanical and ultrasonic lithotripsy technique.The video show our experience.
Home births for high risk women result in high death rates
Journal: BMJ (1998)

Changed criteria for diabetes need further researchIn 1997 the American Diabetes Association changed the diagnostic fasting plasma value for glucose from 7.8 to 7.0 mmol/l.For screening and epidemiological studies they no longer recommended the standard 75 g oral glucose tolerance test recommended by the WHO.The DECODE Study Group's reanalysis of epidemiological studies in eight European countries-more than 26 000 patients-found that the two diagnostic criteria agreed in only 431 of 1517 people classified as diabetic (p 371).Because of this reclassification the group says that the WHO should wait for results of further reanalyses, with focus on prognostic impact, before it considers adopting the ADA criteria.
Haematospermia
Authors: Tamsin Drake, Luke Hanna, Melissa Davies
Journal: BMJ (2016)

#### What you need to know A 40 year old man complains of two episodes when he noticed blood in his ejaculate. He is otherwise well and has no comorbidities. Visible blood in ejaculate—haematospermia or haemospermia—is usually an isolated symptom, and its incidence is unknown. In most cases, it is benign and self limiting, often caused by inflammation or infection of the prostate, urethra, or seminal tract.1 Possible causes are outlined in Box 1. Patients may describe haematuria, urinary frequency, dysuria, and scrotal, pelvic, or perineal pain, particularly at the time of orgasm.2 #### Box 1: Causes of haematospermia ##### Benign ##### Malignant
Pruritus Ani.
Authors: A. J. Byerly
Journal: JAMA (1902)

Coggon, Iowa, July 15, 1902. <h3>To the Editor:</h3> —The recent article inThe Journalby Edmund Andrews illustrating the use of strong heat in the treatment of pruritus ani contains some statements to which I wish to direct attention. In considering the principles involved in the treatment of pruritus by strong heat, Dr. Andrews refers to the domestic practice common among people living in northern latitudes of treating pernios or chilblains by holding each chilblain before a fire as hot as can be borne for one or two minutes, and he speaks of this treatment as being successful and entirely satisfactory. My personal experience with chilblains is not in accord with this statement. The strong heat makes the treatment disagreeable and the chilblain is left tender and sensitive. Therefore, I have modified this domestic custom and immersed the chilblains in water of a temperature of 105 to 110 F. for about ten minutes (until the
Diagnostic Electroencephalography
Authors: W. T. LIBERSON
Journal: American Journal of Psychiatry (1953)

This volume summarizes an extensive program of research in a new and rapidly developing field of neurosurgery.The methods and equipment developed serve as the basis for future clinical investigation.There is little doubt concerning the value and great therapeutic possibilities of this method.The authors have produced a stereotaxic atlas of fundamental importance to those interested in this phase of neurosurgery.This volume is part one of a series.Subsequent parts yet to be published will deal with clinical problems and should prove of greater general interest to the pro-- fession.